Avexitide

What is Avexitide?

Avexitide is the developmental name for exendin-(9-39), the C-terminal 31-amino-acid fragment of the 39-amino-acid Gila monster venom peptide exendin-4. Pharmacologically it is the inverse of every other GLP-1 directory entry on this site: where semaglutide, tirzepatide, liraglutide, and exenatide are GLP-1 receptor *agonists* that enhance insulin secretion, avexitide is a GLP-1 receptor *antagonist* that competitively blocks GLP-1 receptor activation and reduces GLP-1-driven insulin secretion. The N-terminal His-Gly that defines exendin-4's agonist activity is what avexitide lacks. Originally developed by Eiger BioPharmaceuticals as a treatment for two narrow but serious hypoglycemic disorders — post-bariatric hypoglycemia (PBH) and congenital hyperinsulinism (CHI) — the asset was acquired by Amylyx in 2024 and has advanced through Phase 3 for the PBH indication, with FDA Breakthrough Therapy Designation and Orphan Drug Designation supporting an expedited regulatory path.

What Avexitide Is Investigated For

Avexitide has two clinical centers of gravity, both serious hypoglycemic disorders driven by inappropriate insulin secretion. The strongest evidence is in post-bariatric hypoglycemia: Phase 1 and Phase 2 trials (Craig et al. 2018; Tan et al. 2020 in Diabetes, Obesity & Metabolism) demonstrated that subcutaneous avexitide reduces postprandial hypoglycemia, raises the postprandial glucose nadir, and improves associated symptoms in patients with confirmed PBH following Roux-en-Y gastric bypass. The Phase 3 PREVENT trial (sponsored by Amylyx following acquisition of the Eiger program) reported positive topline results in 2025. FDA Breakthrough Therapy Designation (2017) and Orphan Drug Designation support the regulatory path. The second indication is congenital hyperinsulinism — Calabria et al. 2022 (Diabetes Care) and Ng et al. 2018 (Br J Clin Pharmacol pharmacokinetic study) demonstrated that exendin-(9-39) raises glucose and reduces inappropriate insulin secretion in children with CHI. Beyond therapeutics, avexitide has been used extensively as a research probe — infusing it to block GLP-1 signaling allows investigators to dissect how much of an observed insulin response depends on the GLP-1 axis. The honest caveats: avexitide is not approved for any indication as of mid-2026, the target population is narrow (severe symptomatic PBH and CHI rather than common conditions), and long-term safety beyond trial duration is limited.

History & Discovery

Exendin-(9-39) entered the scientific literature in the late 1980s and 1990s as a research tool — once exendin-4 was identified as a GLP-1 receptor agonist, truncating its N-terminus produced a competitive antagonist that became the standard pharmacological probe for blocking GLP-1 signaling. Hundreds of preclinical and translational papers have used exendin-(9-39) to dissect how much of a given physiological or pharmacological insulin response depends on the GLP-1 axis. The therapeutic development arc began later, driven by a recognized clinical need: as Roux-en-Y gastric bypass surgery became increasingly common in the 2000s and 2010s, a meaningful subset of post-bariatric patients (estimated 0.2–5% of RYGB recipients depending on definition) developed severe symptomatic late-postprandial hypoglycemia that did not respond to dietary management. Tracy McLaughlin's group at Stanford was central to establishing that this syndrome was driven primarily by exaggerated GLP-1 release and that GLP-1 receptor blockade reversed it — work culminating in the Salehi et al. 2017 Diabetologia paper and the subsequent therapeutic development program. Eiger BioPharmaceuticals took avexitide forward through Phase 1 (Craig et al. 2018) and Phase 2 (Tan et al. 2020) in PBH, with parallel CHI development (Calabria et al. 2022; Ng et al. 2018). FDA Breakthrough Therapy Designation (2017) and Orphan Drug Designations supported the rare-disease regulatory path. In 2024, Eiger filed for bankruptcy following an unrelated business setback; its avexitide program was acquired by Amylyx Pharmaceuticals, which advanced the Phase 3 PREVENT trial in PBH and reported positive topline results in 2025. As of mid-2026, avexitide is not yet FDA-approved for any indication, with regulatory filings underway. The asset is a prototype for the broader pharmacological logic that GLP-1 signaling is bidirectionally important — agonism for hyperglycemia and obesity, antagonism for hyperinsulinemic hypoglycemia.

How It Works

Avexitide blocks the GLP-1 receptor. GLP-1 is a gut hormone that tells the pancreas to release insulin after meals — useful in normal physiology, but harmful when it goes into overdrive after gastric bypass or in congenital hyperinsulinism. By blocking the receptor, avexitide prevents the inappropriate insulin spike and stops the dangerous low blood sugar that follows.

Avexitide is the C-terminal fragment (residues 9–39) of exendin-4, the full 39-amino-acid GLP-1 receptor agonist from Heloderma suspectum (Gila monster) venom. The first eight N-terminal residues of exendin-4 — particularly His-Gly at positions 1–2 — are required for receptor activation; the remaining C-terminal portion provides high-affinity receptor binding without activation. Truncating the N-terminus produces a competitive antagonist that binds the GLP-1 receptor with affinity comparable to native GLP-1 but does not activate downstream Gs/cAMP/PKA signaling. The net effect is competitive blockade of endogenous GLP-1 action, preventing GLP-1-driven amplification of glucose-stimulated insulin secretion from pancreatic beta cells. In post-bariatric hypoglycemia, the underlying pathophysiology is exaggerated postprandial GLP-1 release from L-cells (driven by the rapid delivery of nutrients to the distal small bowel after Roux-en-Y gastric bypass), producing hyperinsulinemia disproportionate to the glycemic load and reactive hypoglycemia within 1–3 hours of eating. Avexitide blocks the amplification step, restoring more physiologic insulin secretion and preventing the hypoglycemic nadir. In congenital hyperinsulinism, the underlying defect involves dysregulated beta-cell insulin secretion (most commonly via mutations in KATP channel components ABCC8 or KCNJ11); avexitide reduces the GLP-1 contribution to that dysregulated secretion. Subcutaneous administration produces dose-dependent receptor blockade with half-life supporting twice-daily or three-times-daily dosing in the trial regimens.

Evidence Snapshot

Research Gaps & Open Questions

What the current literature has not yet settled about Avexitide:

• 01Long-term safety beyond Phase 3 trial duration — the chronic nature of PBH and CHI means decades of avexitide use is expected, but available safety data extends only through trial follow-up periods.
• 02Pediatric long-term use in CHI — children with CHI may use avexitide for decades; longitudinal growth, development, and cardiovascular outcomes are not yet characterized.
• 03Response heterogeneity in PBH — some patients respond robustly to avexitide while others have partial response; mechanistic predictors of response have not been fully characterized.
• 04Optimal positioning vs. existing PBH therapies — how avexitide should be sequenced with dietary modification, acarbose, diazoxide, somatostatin analogs, and (rarely) partial pancreatectomy is not yet standardized.
• 05Pregnancy and lactation safety — entirely uncharacterized; affected pregnant patients with severe PBH face particular clinical challenges.
• 06Once-daily or extended-release formulations — current twice/thrice daily SC dosing is burdensome; whether a longer-acting formulation could achieve adequate meal-coverage is an active development question.
• 07Use in late-dumping-syndrome-equivalent hypoglycemia after other bariatric procedures (vertical sleeve gastrectomy, biliopancreatic diversion) — most evidence is in post-RYGB; extending to other procedures has limited dedicated data.

Forms & Administration

Subcutaneous injection. Phase 3 trial dosing has used the Lyo (lyophilized) formulation in twice-daily or three-times-daily regimens timed before meals. Self-administration after caregiver/patient training has been used in trials. Not currently available outside clinical trials or expanded-access pathways.

Dosing & Protocols

The ranges below reflect protocols commonly discussed in the literature and by clinicians — not a prescription. Actual dosing for any individual should be determined by a qualified healthcare provider who knows the patient.

Avexitide is investigational as of mid-2026 and not FDA-approved for any indication. Treatment of PBH or CHI requires specialty endocrinology and bariatric medicine care. The information here is for educational reference, not treatment direction.

Timeline of Effects

Common Questions

Who Avexitide Is NOT For

Drug & Supplement Interactions

Avexitide's most clinically important interaction is mechanistic rather than pharmacokinetic: concurrent use with GLP-1 receptor agonists (semaglutide, tirzepatide, liraglutide, exenatide, dulaglutide, mazdutide, retatrutide) is mechanistically contradictory and contraindicated. These drug classes have opposite effects on the GLP-1 receptor; combining them would either neutralize both or produce unpredictable receptor pharmacology. With DPP-4 inhibitors (sitagliptin, linagliptin, etc.) — which prolong endogenous GLP-1 and GIP activity by inhibiting their degradation — the combination is similarly contraindicated. The DPP-4 inhibitor mechanism depends on amplifying endogenous incretin signaling that avexitide is designed to block. With insulin secretagogues (sulfonylureas: glipizide, glyburide; meglitinides: repaglinide, nateglinide) — these drugs stimulate insulin secretion independent of GLP-1 and are not blocked by avexitide. Patients on these agents who develop appropriate hypoglycemia from the secretagogue itself need adjustment of the secretagogue rather than addition of avexitide. Diazoxide is a different class (KATP channel opener that reduces insulin secretion) and has been used off-label for severe refractory PBH and as standard CHI therapy. Avexitide and diazoxide have distinct mechanisms and may potentially be combined for refractory disease — clinical trial protocols have varied. Octreotide (somatostatin analog) similarly has a different mechanism. Acarbose (alpha-glucosidase inhibitor) reduces postprandial carbohydrate absorption and is mechanistically complementary. Given avexitide's narrow approved-population scope, drug interaction concerns center primarily on the GLP-1 axis. Patients on any chronic medication should disclose all therapy to their managing endocrinologist before initiating avexitide.

Safety Profile

Legal Status

Regulatory status changes over time. Verify current local rules with a qualified professional.

Myths & Misconceptions